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Endocrine Disrupting Chemicals (EDC, see the 
dedicated web area http://www.iss.it/inte) can damage 
human and/or animal health by altering the hormone 
function(s). The endocrine system is the most complex 
signalling network in the organism; EDC, therefore, 
may act through a number of mechanisms and targets. 
Accordingly, EDC are a wide and diverse group includ-
ing e.g., pesticides, plasticizers, persistent pollutants, 
natural plant metabolites.
EDC represent a long-standing concern for interna-
tional agencies involved in the risk assessment of chem-
icals, as well as an issue for intense debate among scien-
tists, industries and the public. From the toxicologist’s 
viewpoint, such debate is not pointless at all. EDC are 
hazardous for next generation’s health, since hormones 
are crucial for development, from embryo through to 
puberty. Each hormone regulates several organs and tis-
sues, thus an EDC can hit several targets. For instance, 
experimental studies on the plasticizer bisphenol A, 
considered as an “estrogen-mimicking” EDC, have 
identified multiple targets in developing rodents, such 
as mammary gland, liver, brain, reproductive and im-
mune systems. The susceptibility to such effects may 
also change depending on the sex-related endocrine 
regulation. Last but not least, EDC are widepread in 
environment, products, foods and some may also bioac-
cumulate: thus, EDC pollution may lead to cumulative 
exposures to chemicals sharing the same targets.
Europe and some Member States have devoted sub-
stantial resources to research on EDC for about twenty 
years. Thus one EU citizen could legitimately say “So 
much knowledge gained, stop putting money on re-
search, let’s regulate the hazards”: my answer is “Yes 
and No”.
“Yes” because gaps of knowledge must not prevent 
taking action whenever it is supported by knowledge. 
For instance, current EU regulations on pesticides and 
biocides require that EDC are identified and restricted: 
the available knowledge does allow to identify substanc-
es as EDC, thus, delays would be unjustified.
“No” because the available evidence presents several 
gaps which are definitely relevant for building-up a sci-
ence-based risk assessment.
The first one is an old, yet still ongoing, story. How 
can we define a “safe dose” for EDC? EDC that inter-
act with nuclear receptors may elicit a cellular response 
at very low doses, which may be qualitatively different 
from that elicited at higher doses (e.g., stimulating at 
lower and antagonizing at higher concentrations): re-
search is still needed to understand whether these 
low-dose responses are linked to adverse effects, es-
pecially in developing organisms which are considered 
to be more susceptible. The characterization of dose-
response relationships is one pillar of risk assessment: 
should this framework be modified to take into account 
EDC low-dose effects? And how? 
Then, are we able to assess hazards to all main EDC 
targets? Most EDC research still concentrates on ef-
fects on the reproductive cycle, whose importance can-
not be disputed. Yet, as already mentioned above, major 
hormones do regulate a number of organs and tissues, 
including some (e.g., bone) that are not usually investi-
gated in toxicological testing. The hormone balance is 
paramount to regulate the complex process of neurobe-
havioral development: yet, efforts are still required in 
order to translate research findings into reliable param-
eters to assess the neurodevelopmental impact of EDC. 
Even more important, the current testing tools do not 
appropriately identify effects related to the major, endo-
crine disease of today’s world, type II diabetes; the same 
applies to the endocrine component of obesity, which 
is connected to diabetes in the so-called “metabolic 
syndrome”. Experimental, and to a lesser extent epi-
demiological, research shows that some environmental 
chemicals increase the risk of diabetes and/or obesity; 
in general such substances belong to the small group 
of thoroughly investigated “usual suspects”, like arse-
nic or bisphenol A. The absence of robust endpoints 
and assays jeopardizes the consistent identification of 
substances that elicit effects relevant to such top-class 
public health issue as the metabolic syndrome. Adverse 
outcome pathways (AOP) are a novel toxicological ap-
proach, building causative chains from initiating events 
at molecular level through cellular changes that reflect 
the onset of adversity up to pathological conditions at 
tissue and organism level. Indeed AOP could support 
understanding of the full spectrum of EDC effects. 
Identified or potential EDC are present in our living 
environment. Is there a health risk ongoing? Should ur-
gent measures be taken to reduce such risk? Research 
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needs on EDC include epidemiological studies, which 
currently show a good ground for improvement. A ma-
jor issue may be how to assess the “early exposure-late 
effect” scenario which is the foremost EDC-related 
health problem. In practice, the previous exposure in 
the womb or during early childhood does matter more 
than the current EDC level in body fluids of fully-grown 
adults. How to cope with epidemiological investiga-
tions about the EDC impact on developmental pro-
gramming? An answer could be creating and exploiting 
biobanks, and finding predictive biomarkers of effect 
that can link developmental exposures to adult health 
risks. Not to hint that adult exposure does not matter: 
here too, substantial advances are needed, including 
models and tools for exposure characterization and rel-
evant biomarkers. Biological plausibility of endpoints 
and findings is a main requirement for epidemiologi-
cal studies: “cross-fertilization” between epidemiology 
and toxicology will greatly help. Finally, and again, also 
epidemiological research should take into account sub-
stances other than the “usual suspects”.
All that said, many EDC are useful substances for 
consumers, not just for industry: pesticides to support 
farming, plasticizers, preservatives, sunscreens, flame 
retardants, etc. Yet, restrictions are required to protect 
human health and environmental integrity. Substitution 
of high-concern substances, including EDC, is invoked 
by the European Regulation REACH (Registration, 
Evaluation, Authorisation and Restriction of Chemi-
cals). Candidates for replacing high-concern substances 
might just appear to be less hazardous because their 
toxicity has been insufficiently investigated. The chal-
lenge, therefore, is to develop robust approaches to 
identify safer substitutes for EDC of priority concern; 
this requests the development of time- and cost-effec-
tive screening strategies, making the best possible use 
of non-animal (in silico, in vitro) tools (see the project 
LIFE EDESIA, http://www.iss.it/life).
So, we do not need just “more research” on EDC; 
rather, we need “fit-for-purpose” research to support 
risk managers and policy makers in Europe and world-
wide.
